RESUMO

Permanent right ventricular apical pacing deteriorates cardiac systolic function in some patients. We investigated an alternative site for permanent pacemaker (PPM) lead positioning with the goal of achieving more physiological pacing. A total of 132 patients with bradyarrhythmias underwent PPM implantation at the right ventricular outflow tract (RVOT) with conventional active-fixation leads. A real-time cross-correlation analysis (CCA) was performed using the Synchromax® software (EXO Health, Seattle, WA, USA) to determine the optimal site for ventricular lead implantation based on the cardiac synchrony index. The follow-up period ranged from 6-36 months, and the following parameters were assessed: pacing capture threshold, lead stability, and the need for lead repositioning. Adequate parameters were achieved in 129 patients (98%), and there were no procedure-related complications. At follow-up, no leads were dislodged, pacing thresholds remained stable, and no lead required repositioning. Using real-time CCA as an intraoperative parameter during PPM implantation at the septal RVOT helps to achieve cardiac synchrony in the vast majority of cases. This technique is a simple, effective, and safe way to simplify and standardize PPM implantation at the RVOT.

RESUMO

SUMMARY OBJECTIVE: The use of cardiac implantable electronic devices has increased in recent years. It has also brought some issues. Among these, the complications of cardiac implantable electronic devices infection and pocket hematoma are difficult to manage. It can be fatal with the contribution of patient-related risk factors. In this study, we aimed to find mortality rates in patients who developed cardiac implantable electronic devices infection and pocket hematoma over 5 years. We also investigated the risk factors affecting mortality in patients with cardiac implantable electronic devices. METHODS: A total of 288 cardiac implantable electronic devices patients were evaluated. Demographic details, history, and clinical data of all patients were recorded. Cardiac implantable electronic devices infection was defined according to the modified Duke criteria. The national registry was used to ascertain the mortality status of the patients. The patients were divided into two groups (exitus and survival groups). In addition, the pocket hematoma was defined as significant bleeding at the pocket site after cardiac implantable electronic devices placement. RESULTS: The cardiac implantable electronic devices infection was similar in both groups (p=0.919), and the pocket hematoma was higher in the exitus group (p=0.019). The exitus group had higher usage of P2Y12 inhibitors (p≤0.001) and novel oral anticoagulants (p=0.031). The Cox regression analysis, including mortality-related factors, revealed that renal failure is the most significant risk factor for mortality. Renal failure was linked to a 2.78-fold higher risk of death. CONCLUSION: No correlation was observed between cardiac implantable electronic devices infection and mortality, whereas pocket hematoma was associated with mortality. Furthermore, renal failure was the cause of the highest mortality rate in patients with cardiac implantable electronic devices.

RESUMO

Fundamento: A cardiomiopatia chagásica (CCh) é responsável pelo implante de marcapasso (MP) em muitos pacientes, tendo sido associada a prognóstico adverso. Objetivos: Comparar o prognóstico da população chagásica e não chagásica submetida ao implante de MP e ressincronizador cardíaco. Métodos: Estudo observacional, retrospectivo, que analisou coorte de pacientes submetidos a implante desses dispositivos, em centro terciário, de Outubro 2007 a Dezembro de 2017, comparando o grupo de pacientes chagásicos com os não-chagásicos. O desfecho primário foi a mortalidade por qualquer causa, enquanto os desfechos secundários foram a ocorrência de internação e o desfecho combinado internação e morte. Resultados: Um total de 911 pacientes foram incluídos, sendo que 23,4% apresentavam CCh. Em análise de Cox ajustada por sexo e idade, a doença de Chagas (dCh) não esteve associada ao risco aumentado de morte (HR: 1,14, IC:95%, 0,86-1,51, p=0,365), internação (HR: 0,79, IC:95%, 0,61-1,04, p=0,09) ou desfecho combinado morte e internação (HR: 0,90, IC:95%, 0,72-1,12, p=0,49). Conclusões: A dCh não se associou ao aumento do risco de morte, internação, ou desfecho combinado morte e internação, mesmo após ajuste para sexo e idade. Trabalhos semelhantes ainda não foram publicados na literatura vigente considerando-se especificamente a população chagásica portadora de dispositivos cardíacos, e novos estudos são necessários para se confirmar esses achados

Background: Chagas cardiomyopathy (ChCC) is responsible for the implantation of pacemaker (PM) in many patients and has been associated with an adverse prognosis. Objectives: To compare the prognosis of the chagasic and non-chagasic population undergoing PM and cardiac resynchronizer implantation. Methods: Observational, retrospective study, which analyzed a cohort of patients who underwent implantation of these devices, in a tertiary center, from October 2007 to December 2017, comparing the group of chagasic with non-chagasic patients. The primary outcome was mortality from any cause, while the secondary outcomes were the occurrence of hospitalization and the combined outcome of hospitalization and death. Results: A total of 911 patients were included, of which 23.4% had ChCC. In a Cox analysis adjusted for sex and age, Chagas disease (ChD) was not associated with an increased risk of death (HR: 1.14, CI:95%, 0.86-1.51, p=0.365), hospitalization (HR: 0.79, CI:95%, 0.61-1.04, p=0.09) or combined outcome of death and hospitalization (HR: 0.90, CI:95%, 0.72-1 .12, p=0.49). Conclusions: ChD was not associated with an increased risk of death, hospitalization, or combined outcome of death and hospitalization, even after adjustment for sex and age. Similar studies have not yet been published in the current literature specifically considering the chagasic population with cardiac devices, and new studies are needed to confirm these findings.

Assuntos

RESUMO

Resumen Objetivo: Determinar seguridad y eficacia del marcapasos temporal mediante cable de fijación activa vía yugular y/o subclavia. Métodos: Se analizaron pacientes desde 2017 a 2021 postextracción de marcapasos dependientes de estimulación. Resultados: Se colocó estimulación temporal en 25 pacientes con una edad media de 68 ± 16 años. La media de duración de la estimulación temporal fue cinco días. No se registró mortalidad asociada a la estimulación temporal, sin embargo en un paciente se presentó desplazamiento de cable y falla de captura a los cuatro días de la colocación. Conclusiones: La estimulación temporal mediante cable de fijación activa es segura y eficaz.

Abstract Objective: To determine the efficacy and safety of temporary pacing with an active fixation lead placed trough the internal jugular vein and/or subclavian vein. Methods: We analyzed a consecutive series of 25 out of 73 patients that had a pacemaker extraction and were pacing dependent requiring temporary pacing with an active fixation lead until the new pacemaker implant, from 2017 to 2021. Results: After extraction 25 patients age 68 years ±16 years, required temporary pacing, the media for temporary pacing was 5 days. There were no mortality associated to temporary stimulation. Only one patient (4%) had a complication 4 days after the implant with capture fail due to a microdislogement requiring reintervention. Conclusion: Temporary stimulation through active fixation pacemaker lead it is safe and effective.

RESUMO

Introdução: Pacientes com insuficiência cardíaca e doenças do sistema de condução necessitam de dispositivos para monitoramento dos batimentos cardíacos, como marcapassos permanentes, dispositivos de ressincronização cardíaca ou cardiodesfibriladores implantáveis. A estimulação ventricular direita (EVD) é tradicionalmente o tratamento de escolha. No entanto, estudos demonstraram evidências de dissincronia ventricular, redução da função cardíaca, recorrência de fibrilação atrial e aumento da mortalidade associadas a esta abordagem. O conhecimento dos efeitos adversos das técnicas convencionais justifica a realização de pesquisas para determinar se a estimulação hissiana (EH) é uma técnica que produz maior ativação fisiológica e ventricular mais sincronizada. Objetivo: Avaliar a eficácia da estimulação hissiana comparada à EVD em relação aos parâmetros eletrocardiográficos, ecocardiográficos e clínicos.Material e Métodos: Os critérios de elegibilidade seguiram a estratégia PICOS: P ­ pacientes com indicação de dispositivos cardíacos eletrônicos implantáveis; I ­ estimulação hissiana; C ­ estimulação ventricular direita; O ­ duração do complexo QRS, fração de ejeção, diâmetro ventricular ou classe funcional da New York Heart Association (NYHA); S ­ ensaios clínicos controlados randomizados (ECR) e não randomizados. As buscas foram realizadas nas bases Medline via PubMed, Embase, LILACS e Cochrane Library, realizadas em março de 2023 por três revisores independentes. Resultados: Foram incluídos sete ensaios clínicos comparando as técnicas EH versus EVD quanto aos desfechos investigados. Para a duração do complexo QRS, três estudos encontraram resultado significativamente melhor no grupo intervenção. Para fração de ejeção e classe funcional da NYHA, dois estudos apresentaram resultados significativamente melhores no grupo EH. Quanto ao risco de viés, apenas dois apresentaram risco baixo e médio, quatro apresentaram risco alto em um, dois ou três dos itens avaliados. Conclusões: A técnica EH demonstrou superioridade à técnica convencional, entretanto são necessários ECR de maior qualidade metodológica e meta-análises para verificar a eficácia clínica da técnica, envolvendo maior número de pacientes e tempo de seguimento.

Introduction: Patients with heart failure and cardiac conditions require devices for monitoring the heartbeat, such as permanent pacemakers, cardiac resynchronization devices, or implantable cardioverter defibrillators. Right ventricular stimulation (RVP) has traditionally been the treatment of choice. However, studies have shown evidence of ventricular dyssynchrony, reduced cardiac function, recurrence of atrial fibrillation, and increased mortality associated with this approach. Recognizing the adverse effects of conventional techniques justifies conducting research to determine whether Hissian or His bundle pacing (HPB) stimulation can provide more physiologically synchronized ventricular activation. Objective: The aim is to assess the efficacy of Hissian stimulation compared to right ventricular pacing (RVP) in relation to electrocardiographic, echocardiographic and clinical parameters. Material and Methods: The eligibility criteria will follow the PICOS strategy: P ­ Patients with indication for implantable electronic cardiac devices; I ­ Hissan Stimulation; C ­ Right Ventricular Stimulation; O ­ QRS complex duration, ejection fraction, ventricular diameter and New York Heart Association (NYHA) functional class; S ­ Controlled Trials. Searches were conducted on the Medline via PubMed, Embase, Latin America and Caribbean Health Science Literature Database (LILACS) and Cochrane Library platforms. The searches were performed in March 2023 by three independent reviewers. Results: Seven clinical trials were included, comparing HPB versus RVP techniques regarding the investigated outcomes. For the QRS complex duration, three studies found a significantly better result in the intervention group. For ejection fraction and NYHA functional class, two studies had significantly better results in the HPB group too. Concerning the risk of bias, out of the seven studies included, only two presented low and medium risk, four presented high risk in one, two or three of the items evaluated. Conclusions: The HPB technique has demonstrated superiority to the conventional technique, however, RCT of higher methodological quality and meta-analysis are needed to verify the clinical effectiveness of the technique, involving more patients and longer follow-up time.

Assuntos

RESUMO

Objective: To determine the efficacy and safety of temporary pacing with an active fixation lead placed trough the internal jugular vein and/or subclavian vein. Methods: We analyzed a consecutive series of 25 out of 73 patients that had a pacemaker extraction and were pacing dependent requiring temporary pacing with an active fixation lead until the new pacemaker implant, from 2017 to 2021. Results: After extraction 25 patients age 68 years ±16 years, required temporary pacing, the media for temporary pacing was 5 days. There were no mortality associated to temporary stimulation. Only one patient (4%) had a complication 4 days after the implant with capture fail due to a microdislogement requiring reintervention. Conclusion. Conclusion: Temporary stimulation through active fixation pacemaker lead it is safe and effective.

Objetivo: Determinar seguridad y eficacia del marcapasos temporal mediante cable de fijación activa vía yugular y/o subclavia. Métodos: Se analizaron pacientes desde 2017 a 2021 postextracción de marcapasos dependientes de estimulación. Resultados: Se colocó estimulación temporal en 25 pacientes con una edad media de 68 ± 16 años. La media de duración de la estimulación temporal fue cinco días. No se registró mortalidad asociada a la estimulación temporal, sin embargo en un paciente se presentó desplazamiento de cable y falla de captura a los cuatro días de la colocación. Conclusiones: La estimulación temporal mediante cable de fijación activa es segura y eficaz.

Assuntos

RESUMO

Coordinated and harmonic (synchronous) ventricular electrical activation is essential for better left ventricular systolic function. Intraventricular conduction abnormalities, such as left bundle branch block due to artificial cardiac pacing, lead to electromechanical "dyssynchronopathy" with deleterious structural and clinical consequences. The aim of this review was to describe and improve the understanding of all the processes connecting the several mechanisms involved in the development of artificially induced ventricular dyssynchrony by cardiac pacing, most known as pacing-induced cardiomyopathy (PiCM). The chronic effect of abnormal impulse conduction and nonphysiological ectopic activation by artificial cardiac pacing is suspected to affect metabolism and myocardial perfusion, triggering regional differences in the activation/contraction processes that cause electrical and structural remodeling due to damage, inflammation, and fibrosis of the cardiac tissue. The effect of artificial cardiac pacing on ventricular function and structure can be multifactorial, and biological factors underlying PiCM could affect the time and probability of developing the condition. PiCM has not been included in the traditional classification of cardiomyopathies, which can hinder detection. This article reviews the available evidence for pacing-induced cardiovascular disease, the current understanding of its pathophysiology, and reinforces the adverse effects of right ventricular pacing, especially right ventricular pacing burden (commonly measured in percentage) and its repercussion on ventricular contraction (reflected by the impact on left ventricular systolic function). These effects might be the main defining criteria and determining mechanisms of the pathophysiology and the clinical repercussion seen on patients.

Assuntos